【BioNTech以12.5亿美元收购CureVac，结束数十年竞争】金十数据6月12日讯，BioNTech同意以约12.5亿美元的价格收购前新冠疫苗竞争对手CureVac，促进其不断增长的肿瘤业务。这笔交易为两家公司之间数十年的竞争画上了句号，两家公司的竞争在研发新冠病毒疫苗中达到了白热化。BioNTech与其合作伙伴辉瑞公司赢得了这场竞争，成为欧洲领先的生物技术公司之一。在临床试验证明疗效较差后，CureVac的新冠疫苗从未进入市场。美股盘前，CureVac股价飙升26%，而BioNTech股价上涨1.5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.